Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies

Therapy Developed That May Inhibit Kidney Disorder by Differentiating Disease Processes and Biomarkers

By BiotechDaily International staff writers
Posted on 06 Aug 2013
Print article
Image: A kit used to collect exhaled breath for metabolic analysis in a study of methylmalonic academia (MMA) (Photo courtesy of Maggie Bartlett, NHGRI; NIH Clinical Center, Bethesda, MD, USA).
Image: A kit used to collect exhaled breath for metabolic analysis in a study of methylmalonic academia (MMA) (Photo courtesy of Maggie Bartlett, NHGRI; NIH Clinical Center, Bethesda, MD, USA).
A group of investigators has overcome a major biologic obstacle in an effort to find enhanced treatments for patients with a rare disease called methylmalonic acidemia (MMA). The scientists, utilizing genetically engineered mice, identified a series of biomarkers of kidney damage—a key characteristic of the disorder—and demonstrated that antioxidant therapy protected kidney function in the mice.

Researchers from the US National Human Genome Research Institute (NHGRI; Bethesda, MD, USA), part of the National Institutes of Health (NIH), substantiated the same biomarkers in 46 patients with MMA seen at the NIH Clinical Center. The biomarkers offer new tools for monitoring disease progression and the effects of therapies, both of which will be helpful in the researchers' design of clinical trials for this disease.

The discovery, reported in the July 29, 2013, advance online issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS), creates the possibility for use of antioxidant therapy in a clinical trial for patients with MMA. It also demonstrates the processes by which mitochondrial dysfunction affects kidney disease. Mitochondrial dysfunction is a problem not only in rare disorders, such as MMA, but also in a broad range of common disorders, such as diabetes, obesity, and cancer.

Related Links:

National Human Genome Research Institute



Print article

Channels

Genomics/Proteomics

view channel
Image: Top: Overview of the structure of T-STAR STAR domain in complex with AUUAAA RNA. Bottom left: close up view of the specific recognition of the RNA. Bottom right: close up view of the KH dimerization interface (Photo courtesy of the University of Leicester).

Atomic Structures of Alternative Splicing Regulator Proteins May Lead to New Anticancer Drugs

A detailed structural analysis of two RNA-binding proteins that regulate alternate splicing of gene expression, which can lead to various types of cancer, is expected to aid in the development of drugs... Read more

Drug Discovery

view channel
Image: Naturally occurring clay from Kisameet Bay, Canada, exhibits potent antibacterial activity against multidrug-resistant pathogens (Photo courtesy of Kisameet Glacial Clay Inc.).

Antibiotic Resistant Bacteria Succumb to Treatment with Unique Natural Clay

A team of Canadian medical microbiologists has demonstrated the potential use of a unique type of natural clay for treating pathogenic bacteria that have become resistant to the commonly used antibiotics.... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.